NIH knowingly, intentionally, and recklessly misappropriated $87 million of NIH grants to Frederick National Laboratory for Cancer Research for gain-of-function research on cancer-causing induced pluripotent stem cell (iPSC) based organoids of NCI and NIAID, the same lab where Fauci and Francis Collins manufactured their cancer-causing mRNA vaccines leading to turbo cancer.

NIH knowingly, intentionally, and recklessly misappropriated $87 million of NIH grants to Frederick National Laboratory for Cancer Research for gain-of-function research on cancer-causing induced pluripotent stem cell (iPSC) based organoids of NCI and NIAID, the same lab where Fauci and Francis Collins manufactured their cancer-causing mRNA vaccines leading to turbo cancer.

Last month, NIH knowingly, intentionally, and recklessly misappropriated $87 million of NIH grants to Frederick National Laboratory for Cancer Research for gain-of-function research on cancer-causing induced pluripotent stem cell (iPSC) based organoids of NCI and NIAID, the same lab where Fauci and Francis Collins manufactured their cancer-causing mRNA vaccines leading to turbo cancer we see today. The very corrupt NIH acting director Nicole Kleinstreuer, a hardcore deep state Fauci follower, is dishonest and has no scientific integrity by deliberately omitting any information about their organoids, not stating the basic but critical scientific fact that their organoids are in fact a fraud, faked with induced pluripotent stem cells (iPSC) --- the reprogrammed cancer cells containing oncogenes and an adult stem cell scam, and not telling the public that they used faked data in their iPSC grant applications and awards against NIH grants and research integrity policies.

I am sure NIH acting director Nicole Kleinstreuer and all NIH’s best have the full scientific knowledge that iPSC are cancer cells and fraud, and misappropriation of public fund is a serious crime. Former HHS Head Kathleen Sebelius and former NIH director Francis Collins knowingly defrauded the investing public by deliberately and recklessly misappropriation of tens of billions of taxpayer dollars into iPSC Ponzi scheme of the Bush Administration during the Obama Administration through NIH grants and HHS contracts. In Sept 2021, NIH director Francis Collins suddenly resigned for having knowingly, intentionally, and recklessly misappropriated tens of billions of NIH grants to iPSC scam. Obama held a farewell party for Francis Collins and had Biden/Harris white house stop HHS/NIH from making formal announcement for Francis Collins’ wrong doing. In January 2022, Biden white house science advisor Eric Lander resigned for his scientific misconduct in iPSC, which they covered up as staff dispute. President Trump signed EO to eliminate fraud and waste. However, NIH not only do not eliminate billions of existing iPSC fraud and waste of previous Biden/Harris administration, but also continue to knowingly, intentionally, and recklessly misappropriate taxpayer money to more iPSC fraud and waste of former NIH director Francis Collins against President Trump EO and priorities. Eliezer Masliah Alzheimer scientific misconduct is all over the news, but NIH continue to waste taxpayer money by knowingly, intentionally, and recklessly misappropriating hundreds of millions of awards to his associates and his company all based on his scientific fraud against President Trump’s EO and priorities.

The root cause of the worsening replication crisis, skyrocketing biomedical paper retractions, and “valley of death” in drug development is the status quo of mainstream biomedical research that overwhelmingly employs non-human, lower or simple organism models or systems. Those simple or lower organism-based tools, methods, or technologies often don’t work for humans. And the ideas or leads generated from those non-human, lower or simple organism models or systems have little implications for the prevention and treatment of human diseases, some even fundamentally flawed. As a result, the "publish or perish" culture often forces many professors and researchers to fake their data in order to get funding or generate profits, which is compounded by the fact that government funding agencies, pharmaceutical companies, and academic institutions do not really look into scientific misconduct and replication crisis because of all the funding or profits tied to it, leading to the worsening replication crisis and skyrocketing biomedical paper retractions.

One of the biggest opportunities of advancing the frontier sciences in human development and disorders underlying medicine and public health is provided by human embryonic stem cell (hESC) research. Due to the restriction on human embryonic and fetal materials available for study, there is a fundamental gap in our knowledge regarding the molecular networks and pathways underlying human development. Derivation of hESC provides powerful in vitro model systems to remove limitations at the cellular or biological systems levels that stymie progress towards developing human-based tools and platforms that can apply to a broad range of human diseases.

I am the first person who proposed to use hESC and their derivatives as alternatives to animal testing over 10 years ago, which was written is my hESC publications and book. PETA and advocacy groups used my publications and book to push Congress to pass FDA Modernization Act 2.0 to legitimize alternatives to animal testing for advancing a drug or product to human trials. Enacting such a law for a drastic change in FDA regulation, passed by Congress and welcomed by animal welfare groups, was only made possible by the advances in hESC research that have begun to offer increasingly viable alternatives to animal testing.

Human embryo-originated hESC and their cell/tissue/organ products/models offer viable, adequate, timely, the most cost-effective, the most sensitive, and superior alternatives with higher quality and safety standards to current animal testing systems and other human adult cell-based testing systems. hESC are derived from human embryos, negating the species-species differences observed in animal testing. hESC and their derivatives have very low tolerance threshold and are highly sensitive to any toxic chemicals/drugs/vaccines, providing more timely, predictive, reliable alternative methods to current animal testing systems and other human adult cell-based testing systems, ensuring higher quality and safety standards and reducing the time and cost. hESC-based human cell/tissue/organ products or models offer rapid, cost-effective, and high-fidelity safety evaluation of developmental toxins with sensitivity equivalent to vulnerable children, infants, and fetus. See sdrmi.org for more.

Many of the new approach methodologies (NAMs) in FDA reducing animal testing roadmap, such as adult-cell or reprogramed-adult-cell based organ-on-a-chip systems, computational modeling, and advanced in vitro assays, are unable to provide higher quality and safety standards to animal testing. For example, organ chips and organoids based on adult stem/cancer cells (e.g., induced pluripotent stem cells [iPSC] that are in fact adult cells reprogrammed with oncogenes or actually cancer cells) have proven to be inadequate as alternatives to animal toxicity testing because the tolerance threshold of adult/cancer cells/iPSC to toxic chemicals/drugs is much higher than the tolerance threshold of normal human tissues or organs. Such as, the drugs screened by the liver chips of Emulate based on iPSC/cancer-cells either failed in clinical trials because they were toxic to the liver or were approved for market but then withdrawn or scaled back because of liver damage. In addition, reprogrammed-adult-cell or iPSC-based organoids or organ-on-a-chip systems do not authentically replicate the in vivo human development or organ systems, insensitive to any toxic chemicals/drugs/vaccines/products, inadequate and unreliable to test the safety of chemicals/drugs/vaccines/products.

Exploring viable, adequate, superior alternatives with higher quality and safety standards to animal testing, such as human embryo-originated hESC and their cell/tissue/organ products/models, should be NIH/FDA’s primary initial focus in its proposed “Roadmap to Reducing Animal Testing in Preclinical Safety Studies”, in order to ensure the safety and efficacy to justify an IND application for the proposed clinical investigation.